Abstract

Sickle cell disease is now a chronic adult illness characterized by progressive multiorgan failure, particularly involving the brain and kidney. The etiology is multifactorial; it includes hemolysis and nitric oxide deficiency. As patients age, most experience neurologic insult. Twenty-five percent of older adults have had a clinical stroke and at least half of the population have had a silent infarct, cortical atrophy, and neurocognitive impairment. Periodic screening with neuroimaging and neurocognitive testing is recommended. Identification and correction of modifiable risk factors such as nocturnal hypoxemia, obstructive sleep apnea, and physical exercise programs should be implemented. Patients with neurocognitive impairment require cognitive remediation and educational accommodations. Chronic renal disease occurs in 25% of older adults and results in 50% of their deaths. Renal failure often develops insidiously. It can be prevented or minimized by early screening and treatment of modifiable risk factors including hypertension and microalbuminuria. There is an increasing number of therapeutic options, including inhibitors of the renin angiotensin system, angiotensin-II receptor blockers, endothelin-1 receptor antagonist, and haptoglobin therapy. Patients with sickle cell disease have increased mortality rates from renal failure compared with nonsickle cell patients, in part from a lack of access to early multidisciplinary care, including timely initiation of dialysis and renal transplantation.

MeSH

Hematologic Diseases, Anemia, Sickle Cell, Renin-Angiotensin System, Angiotensins, Risk Factors, Cells, Therapeutics, Endothelin-1, Receptor, Endothelin A, Exercise

Cited by

• Type 2 diabetes mellitus burdens among adults with sickle cell disease: A 12-year single health system-based cohort analysis. EJHaem, 2021
• Oral manifestations of sickle cell disease. Br Dent J, 2019
• Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018. MMWR Surveill Summ, 2022
• Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. Semin Hematol, 2019
• Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts. PLoS One, 2020
• Outcomes following kidney transplantation in patients with sickle cell disease: The impact of automated exchange blood transfusion. PLoS One, 2020
• Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. Clin Pharmacol Drug Dev, 2022
• Hyponatremia in Patients with Hematologic Diseases. J Clin Med, 2020
• Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease. Curr Ther Res Clin Exp, 2023
• Targeting P-selectin and interleukin-1β in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition. Haematologica, 2025
• A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease. Curr Pain Headache Rep, 2020
• Mortality from sickle cell disease in Brazil. PLOS Glob Public Health, 2025
• Heme Induces IL-6 and Cardiac Hypertrophy Genes Transcripts in Sickle Cell Mice. Front Immunol, 2021
• Mortality trends in sickle cell patients. Am J Blood Res, 2020
• Cardiac expression of HMOX1 and PGF in sickle cell mice and haem-treated wild type mice dominates organ expression profiles via Nrf2 (Nfe2l2). Br J Haematol, 2020
• Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease. Ann Intensive Care, 2025
• Optimal disease management and health monitoring in adults with sickle cell disease. Hematology Am Soc Hematol Educ Program, 2020
• The Resolution of a Cerebrovascular Accident With Phlebotomy in a Hemodialysis Patient With Sickle Cell Disease. Cureus, 2023
• The Montreal cognitive assessment as a cognitive screening tool in sickle cell disease: Associations with clinically significant cognitive domains. Br J Haematol, 2022
• How I treat the older adult with sickle cell disease. Blood, 2019